257 related articles for article (PubMed ID: 33753551)
1. AP-2α Regulates S-Phase and Is a Marker for Sensitivity to PI3K Inhibitor Buparlisib in Colon Cancer.
Beck AC; Cho E; White JR; Paemka L; Li T; Gu VW; Thompson DT; Koch KE; Franke C; Gosse M; Wu VT; Landers SR; Pamatmat AJ; Kulak MV; Weigel RJ
Mol Cancer Res; 2021 Jul; 19(7):1156-1167. PubMed ID: 33753551
[TBL] [Abstract][Full Text] [Related]
2. Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib).
Matas-Céspedes A; Rodriguez V; Kalko SG; Vidal-Crespo A; Rosich L; Casserras T; Balsas P; Villamor N; Giné E; Campo E; Roué G; López-Guillermo A; Colomer D; Pérez-Galán P
Clin Cancer Res; 2014 Jul; 20(13):3458-71. PubMed ID: 24799524
[TBL] [Abstract][Full Text] [Related]
3. Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
Sahin I; Azab F; Mishima Y; Moschetta M; Tsang B; Glavey SV; Manier S; Zhang Y; Sacco A; Roccaro AM; Azab AK; Ghobrial IM
Am J Hematol; 2014 Nov; 89(11):1030-6. PubMed ID: 25060991
[TBL] [Abstract][Full Text] [Related]
4. Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.
Netland IA; Førde HE; Sleire L; Leiss L; Rahman MA; Skeie BS; Miletic H; Enger PØ; Goplen D
J Neurooncol; 2016 Aug; 129(1):57-66. PubMed ID: 27283525
[TBL] [Abstract][Full Text] [Related]
5. The AP-2alpha transcription factor is required for the ganglioside GM3-stimulated transcriptional regulation of a PTEN gene.
Choi HJ; Chung TW; Kim SJ; Cho SY; Lee YS; Lee YC; Ko JH; Kim CH
Glycobiology; 2008 May; 18(5):395-407. PubMed ID: 18316341
[TBL] [Abstract][Full Text] [Related]
6. Vitamin C sensitizes triple negative breast cancer to PI3K inhibition therapy.
Mustafi S; Camarena V; Qureshi R; Sant DW; Wilkes Z; Bilbao D; Slingerland J; Kesmodel SB; Wang G
Theranostics; 2021; 11(8):3552-3564. PubMed ID: 33664847
[No Abstract] [Full Text] [Related]
7. Targeting the PI3K signaling pathway in KRAS mutant colon cancer.
Hong S; Kim S; Kim HY; Kang M; Jang HH; Lee WS
Cancer Med; 2016 Feb; 5(2):248-55. PubMed ID: 26715098
[TBL] [Abstract][Full Text] [Related]
8. Loss of AP-2alpha results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo.
Schwartz B; Melnikova VO; Tellez C; Mourad-Zeidan A; Blehm K; Zhao YJ; McCarty M; Adam L; Bar-Eli M
Oncogene; 2007 Jun; 26(28):4049-58. PubMed ID: 17224907
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
Anderson JL; Park A; Akiyama R; Tap WD; Denny CT; Federman N
PLoS One; 2015; 10(9):e0133610. PubMed ID: 26402468
[TBL] [Abstract][Full Text] [Related]
10. Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.
Mundt F; Rajput S; Li S; Ruggles KV; Mooradian AD; Mertins P; Gillette MA; Krug K; Guo Z; Hoog J; Erdmann-Gilmore P; Primeau T; Huang S; Edwards DP; Wang X; Wang X; Kawaler E; Mani DR; Clauser KR; Gao F; Luo J; Davies SR; Johnson GL; Huang KL; Yoon CJ; Ding L; Fenyö D; Ellis MJ; Townsend RR; Held JM; Carr SA; Ma CX
Cancer Res; 2018 May; 78(10):2732-2746. PubMed ID: 29472518
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.
McPherson V; Reardon B; Bhayankara A; Scott SN; Boyd ME; Garcia-Grossman IR; Regazzi AM; McCoy AS; Kim PH; Al-Ahmadie H; Ostrovnaya I; Roth AJ; Farooki A; Berger MF; Rosenberg JE; Solit DB; Van Allen E; Milowsky MI; Bajorin DF; Iyer G
Cancer; 2020 Oct; 126(20):4532-4544. PubMed ID: 32767682
[TBL] [Abstract][Full Text] [Related]
12. AP-2α-Mediated Activation of E2F and EZH2 Drives Melanoma Metastasis.
White JR; Thompson DT; Koch KE; Kiriazov BS; Beck AC; van der Heide DM; Grimm BG; Kulak MV; Weigel RJ
Cancer Res; 2021 Sep; 81(17):4455-4470. PubMed ID: 34210752
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
Maira SM; Pecchi S; Huang A; Burger M; Knapp M; Sterker D; Schnell C; Guthy D; Nagel T; Wiesmann M; Brachmann S; Fritsch C; Dorsch M; Chène P; Shoemaker K; De Pover A; Menezes D; Martiny-Baron G; Fabbro D; Wilson CJ; Schlegel R; Hofmann F; García-Echeverría C; Sellers WR; Voliva CF
Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
[TBL] [Abstract][Full Text] [Related]
14. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
Kim HJ; Lee SY; Kim CY; Kim YH; Ju W; Kim SC
Oncotarget; 2017 Jan; 8(4):6608-6622. PubMed ID: 28036259
[TBL] [Abstract][Full Text] [Related]
15. Aldose reductase inhibition prevents colon cancer growth by restoring phosphatase and tensin homolog through modulation of miR-21 and FOXO3a.
Saxena A; Tammali R; Ramana KV; Srivastava SK
Antioxid Redox Signal; 2013 Apr; 18(11):1249-62. PubMed ID: 22978663
[TBL] [Abstract][Full Text] [Related]
16. Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance.
Safaroghli-Azar A; Bashash D; Kazemi A; Pourbagheri-Sigaroodi A; Momeny M
Eur J Pharmacol; 2019 Jan; 842():89-98. PubMed ID: 30401630
[TBL] [Abstract][Full Text] [Related]
17. Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.
Liang YC; Wu HG; Xue HJ; Liu Q; Shi LL; Liu T; Wu G
J Huazhong Univ Sci Technolog Med Sci; 2013 Dec; 33(6):845-851. PubMed ID: 24337846
[TBL] [Abstract][Full Text] [Related]
18. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2
Packer LM; Geng X; Bonazzi VF; Ju RJ; Mahon CE; Cummings MC; Stephenson SA; Pollock PM
Mol Cancer Ther; 2017 Apr; 16(4):637-648. PubMed ID: 28119489
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.
Brachmann SM; Kleylein-Sohn J; Gaulis S; Kauffmann A; Blommers MJ; Kazic-Legueux M; Laborde L; Hattenberger M; Stauffer F; Vaxelaire J; Romanet V; Henry C; Murakami M; Guthy DA; Sterker D; Bergling S; Wilson C; Brümmendorf T; Fritsch C; Garcia-Echeverria C; Sellers WR; Hofmann F; Maira SM
Mol Cancer Ther; 2012 Aug; 11(8):1747-57. PubMed ID: 22653967
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
Li Z; Xu X; Li Y; Zou K; Zhang Z; Xu X; Liao Y; Zhao X; Jiang W; Yu W; Guo W; Chen Y; Li Y; Chen M; Deng WG; Li L; Zou L
Cell Physiol Biochem; 2018; 45(5):1772-1786. PubMed ID: 29495002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
